secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2026-08-11T20:30:18+00:00
Accession:  0001193125-26-344787
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical amends PermeaDerm agreements: higher revenue share, EU/UK/AU expansion option
--------------------------------------------------------------------------------

- $500,000 fee gives AVITA right of first offer/refusal to expand exclusive PermeaDerm distribution to EU, UK, Australia.
- Revenue share from PermeaDerm rises to 67% (sheet) and 80% (glove) from July 1, 2026; extra payments if gross margin >50% (sheet) or >35% (glove).
- Growth minimums set: $1.0M in 2026, then 20% annual growth to $2.0736M by 2030; prior minimums waived.
- Stedical can sell in certain U.S. markets; AVITA supplies at cost +10%. For OUS (Asia) sales, price $200/carton + 10% manufacturing fee up to 1,600 cartons.
- Milestone payments: AVITA pays $1M if total sales exceed $45M, and $1.5M if exceed $90M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526344787/0001193125-26-344787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312526344787/rcel-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-344787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer